Pregnancy in people with inflammatory bowel disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational analysis using the EPIMAD registry to describe IBD course before, during, and after pregnancy in 945 women. Investigators will cross-link IBD history with pregnancy, postpartum, and breastfeeding data to count flares and timing of disease activity. Eligible participants are women aged 18–50 diagnosed with Crohn's disease or ulcerative colitis between 1988 and 2018 who lived in the Somme and had at least one pregnancy. No interventional treatments are given as part of this project; it uses existing registry records from CHU Amiens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* women between 18 and 50 years old
* MICI diagnosed between 1988 and 2018
* included in EPIMAD registry
* living in Somme
* having had at least one pregnancy

Exclusion Criteria:

* women who has not had pregnancy
* not included in EPIMAD register

Where it's running

• CHU Amiens
  Amiens, France Recruiting

Study contacts

• Study coordinator: Arthur FOULON, Pr
• Email: foulon.arthur@chu-amiens.fr
• Phone: 33+3 22 08 73 82

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy

  This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.

  Recruiting at 5 sites Austin Health · Hobart and 6 other locations · NCT07916727

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• Maternal and infant microbiome links to infant gut inflammation and pregnancy outcomes in people with IBD

  This project will see if mothers' microbiomes, diets, and breastmilk are linked to infant gut inflammation (measured by fecal calprotectin) in pregnant people with and without IBD.

  Recruiting University of British Columbia · Vancouver, British Columbia and 1 other locations · NCT07385807

• Evaluating Upadacitinib for Inflammatory Bowel Disease

  This study is testing how well the oral medication Upadacitinib works for people in China with Inflammatory Bowel Disease who haven't responded to other treatments.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT06780683

• Continued TAK-279 treatment in adults with ulcerative colitis or Crohn's disease

  Adults with moderate to severe ulcerative colitis or Crohn's disease who responded to earlier TAK-279 can continue TAK-279 for up to two years to see if it remains safe and lowers bowel inflammation and symptoms.

  Recruiting at 16 sites Phase 2 Takeda · Glen Burnie, Maryland and 15 other locations · NCT06764615

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.